Published in Microvasc Res on September 19, 2007
Abnormal lymphangiogenesis in idiopathic pulmonary fibrosis with insights into cellular and molecular mechanisms. Proc Natl Acad Sci U S A (2009) 1.21
Listeria and Salmonella bacterial vectors of tumor-associated antigens for cancer immunotherapy. Semin Immunol (2010) 1.09
Sunitinib inhibits lymphatic endothelial cell functions and lymph node metastasis in a breast cancer model through inhibition of vascular endothelial growth factor receptor 3. Breast Cancer Res (2011) 0.99
Identification of genes regulating migration and invasion using a new model of metastatic prostate cancer. BMC Cancer (2014) 0.98
The role of interleukin 17 in tumour proliferation, angiogenesis, and metastasis. Mediators Inflamm (2014) 0.98
Drug resistance associated with antiangiogenesis therapy. Semin Cancer Biol (2009) 0.95
Changes in specialized blood vessels in lymph nodes and their role in cancer metastasis. J Transl Med (2012) 0.94
Regulation of epithelial plasticity by miR-424 and miR-200 in a new prostate cancer metastasis model. Sci Rep (2013) 0.91
The role of EMT and MET in cancer dissemination. Connect Tissue Res (2015) 0.84
Interaction between the extracellular matrix and lymphatics: consequences for lymphangiogenesis and lymphatic function. Matrix Biol (2010) 0.84
VEGF-D-induced draining lymphatic enlargement and tumor lymphangiogenesis promote lymph node metastasis in a xenograft model of ovarian carcinoma. Reprod Biol Endocrinol (2014) 0.80
The Contribution of Angiogenesis to the Process of Metastasis. Cancer J (2015) 0.80
Lymphangiogenesis and metastasis--a closer look at the neuropilin/semaphorin3 axis. Microvasc Res (2014) 0.78
Novel application assigned to toluquinol: inhibition of lymphangiogenesis by interfering with VEGF-C/VEGFR-3 signalling pathway. Br J Pharmacol (2016) 0.77
Tumor angiogenesis: therapeutic implications. N Engl J Med (1971) 35.36
Neuropilin-1 is expressed by endothelial and tumor cells as an isoform-specific receptor for vascular endothelial growth factor. Cell (1998) 10.32
Distinct roles of the receptor tyrosine kinases Tie-1 and Tie-2 in blood vessel formation. Nature (1995) 8.12
Induction of tumor lymphangiogenesis by VEGF-C promotes breast cancer metastasis. Nat Med (2001) 7.78
Vascular endothelial growth factor C is required for sprouting of the first lymphatic vessels from embryonic veins. Nat Immunol (2003) 7.42
Expression of the fms-like tyrosine kinase 4 gene becomes restricted to lymphatic endothelium during development. Proc Natl Acad Sci U S A (1995) 7.11
Angiopoietin-2 is required for postnatal angiogenesis and lymphatic patterning, and only the latter role is rescued by Angiopoietin-1. Dev Cell (2002) 6.41
Hyperplasia of lymphatic vessels in VEGF-C transgenic mice. Science (1997) 6.37
The anti-angiogenic basis of metronomic chemotherapy. Nat Rev Cancer (2004) 6.32
VEGF-A stimulates lymphangiogenesis and hemangiogenesis in inflammatory neovascularization via macrophage recruitment. J Clin Invest (2004) 5.59
VEGF-D promotes the metastatic spread of tumor cells via the lymphatics. Nat Med (2001) 5.52
Critical factors in the biology of human cancer metastasis: twenty-eighth G.H.A. Clowes memorial award lecture. Cancer Res (1990) 5.41
A novel vascular endothelial growth factor, VEGF-C, is a ligand for the Flt4 (VEGFR-3) and KDR (VEGFR-2) receptor tyrosine kinases. EMBO J (1996) 5.33
Lymphatic metastasis in the absence of functional intratumor lymphatics. Science (2002) 5.32
Metastasis: quantitative analysis of distribution and fate of tumor emboli labeled with 125 I-5-iodo-2'-deoxyuridine. J Natl Cancer Inst (1970) 4.88
Interferon alfa-2a therapy for life-threatening hemangiomas of infancy. N Engl J Med (1992) 4.76
Vascular endothelial growth factor-C-mediated lymphangiogenesis promotes tumour metastasis. EMBO J (2001) 4.70
Inhibition of lymphangiogenesis with resulting lymphedema in transgenic mice expressing soluble VEGF receptor-3. Nat Med (2001) 4.50
Vascular endothelial growth factor D (VEGF-D) is a ligand for the tyrosine kinases VEGF receptor 2 (Flk1) and VEGF receptor 3 (Flt4). Proc Natl Acad Sci U S A (1998) 4.48
Metastatic patterns in adenocarcinoma. Cancer (2006) 4.16
PDGF-BB induces intratumoral lymphangiogenesis and promotes lymphatic metastasis. Cancer Cell (2004) 4.12
VEGF-A induces tumor and sentinel lymph node lymphangiogenesis and promotes lymphatic metastasis. J Exp Med (2005) 3.98
Lymphangiogenesis and cancer metastasis. Nat Rev Cancer (2002) 3.90
Complete and specific inhibition of adult lymphatic regeneration by a novel VEGFR-3 neutralizing antibody. J Natl Cancer Inst (2005) 3.58
Suppression of tumor lymphangiogenesis and lymph node metastasis by blocking vascular endothelial growth factor receptor 3 signaling. J Natl Cancer Inst (2002) 3.44
Vascular endothelial growth factor C promotes tumor lymphangiogenesis and intralymphatic tumor growth. Cancer Res (2001) 3.38
Identification of vascular lineage-specific genes by transcriptional profiling of isolated blood vascular and lymphatic endothelial cells. Am J Pathol (2003) 3.35
Vascular permeability factor/vascular endothelial growth factor induces lymphangiogenesis as well as angiogenesis. J Exp Med (2002) 3.16
Clinical features and prognosis of patients with extrahepatic metastases from hepatocellular carcinoma. World J Gastroenterol (2007) 3.14
Critical determinants of metastasis. Semin Cancer Biol (2002) 3.12
Concurrent induction of lymphangiogenesis, angiogenesis, and macrophage recruitment by vascular endothelial growth factor-C in melanoma. Am J Pathol (2001) 2.89
Lymph node metastasis from soft tissue sarcoma in adults. Analysis of data from a prospective database of 1772 sarcoma patients. Ann Surg (1993) 2.87
Tumor lymphangiogenesis: a novel prognostic indicator for cutaneous melanoma metastasis and survival. Am J Pathol (2003) 2.81
Abnormal lymphatic vessel development in neuropilin 2 mutant mice. Development (2002) 2.68
Molecular characterization of lymphatic endothelial cells. Proc Natl Acad Sci U S A (2002) 2.68
VEGF-C-induced lymphangiogenesis in sentinel lymph nodes promotes tumor metastasis to distant sites. Blood (2006) 2.66
Outcomes of radical cystectomy for transitional cell carcinoma of the bladder: a contemporary series from the Bladder Cancer Research Consortium. J Urol (2006) 2.51
Vascular endothelial cell growth factor receptor 3-mediated activation of lymphatic endothelium is crucial for tumor cell entry and spread via lymphatic vessels. Cancer Res (2005) 2.48
Imaging steps of lymphatic metastasis reveals that vascular endothelial growth factor-C increases metastasis by increasing delivery of cancer cells to lymph nodes: therapeutic implications. Cancer Res (2006) 2.42
Inhibition of VEGFR-3 activation with the antagonistic antibody more potently suppresses lymph node and distant metastases than inactivation of VEGFR-2. Cancer Res (2006) 2.40
Tumor-induced sentinel lymph node lymphangiogenesis and increased lymph flow precede melanoma metastasis. Am J Pathol (2007) 2.40
Intratumoral lymphatics are essential for the metastatic spread and prognosis in squamous cell carcinomas of the head and neck region. Cancer Res (2003) 2.39
Angiogenesis promoted by vascular endothelial growth factor: regulation through alpha1beta1 and alpha2beta1 integrins. Proc Natl Acad Sci U S A (1997) 2.32
Blockade of vascular endothelial growth factor receptor-3 signaling inhibits fibroblast growth factor-2-induced lymphangiogenesis in mouse cornea. Proc Natl Acad Sci U S A (2002) 2.30
Proinflammatory cytokines regulate expression of the lymphatic endothelial mitogen vascular endothelial growth factor-C. J Biol Chem (1998) 2.28
VEGF-A promotes tissue repair-associated lymphatic vessel formation via VEGFR-2 and the alpha1beta1 and alpha2beta1 integrins. FASEB J (2004) 2.27
VEGF-D is the strongest angiogenic and lymphangiogenic effector among VEGFs delivered into skeletal muscle via adenoviruses. Circ Res (2003) 2.25
A feasibility trial of antiangiogenic (metronomic) chemotherapy in pediatric patients with recurrent or progressive cancer. J Pediatr Hematol Oncol (2005) 2.14
Semaphorin 3F, a chemorepulsant for endothelial cells, induces a poorly vascularized, encapsulated, nonmetastatic tumor phenotype. J Clin Invest (2004) 2.03
Dose-dependent response of FGF-2 for lymphangiogenesis. Proc Natl Acad Sci U S A (2004) 1.98
Lack of lymphatic vascular specificity of vascular endothelial growth factor receptor 3 in 185 vascular tumors. Cancer (1999) 1.97
Neuropilins in neoplasms: expression, regulation, and function. Exp Cell Res (2006) 1.93
Hepatocyte growth factor promotes lymphatic vessel formation and function. EMBO J (2005) 1.89
Endogenous angiogenesis inhibitors. APMIS (2004) 1.89
Neuropilin-2 interacts with VEGFR-2 and VEGFR-3 and promotes human endothelial cell survival and migration. Blood (2006) 1.88
Structure, function, and molecular control of the skin lymphatic system. J Investig Dermatol Symp Proc (2000) 1.81
Tyrosine kinase inhibitors of vascular endothelial growth factor receptors in clinical trials: current status and future directions. Oncologist (2006) 1.80
VEGF-C induced lymphangiogenesis is associated with lymph node metastasis in orthotopic MCF-7 tumors. Int J Cancer (2002) 1.80
Functional interaction of VEGF-C and VEGF-D with neuropilin receptors. FASEB J (2006) 1.79
Involvement of vascular endothelial growth factor receptor-3 in maintenance of integrity of endothelial cell lining during tumor angiogenesis. Blood (2000) 1.76
Angiopoietin-1 promotes LYVE-1-positive lymphatic vessel formation. Blood (2005) 1.75
Inhibition of lymphogenous metastasis using adeno-associated virus-mediated gene transfer of a soluble VEGFR-3 decoy receptor. Cancer Res (2005) 1.73
Vascular endothelial growth factor receptor 3 is involved in tumor angiogenesis and growth. Cancer Res (2007) 1.73
Insulin-like growth factors 1 and 2 induce lymphangiogenesis in vivo. Proc Natl Acad Sci U S A (2005) 1.72
Tumor and lymph node lymphangiogenesis--impact on cancer metastasis. J Leukoc Biol (2006) 1.72
Angiopoietin-1 promotes lymphatic sprouting and hyperplasia. Blood (2005) 1.71
Vascular endothelial growth factor-a promotes peritumoral lymphangiogenesis and lymphatic metastasis. Cancer Res (2005) 1.64
Prox1 promotes lineage-specific expression of fibroblast growth factor (FGF) receptor-3 in lymphatic endothelium: a role for FGF signaling in lymphangiogenesis. Mol Biol Cell (2005) 1.62
Angiopoietins in tumours: the angiogenic switch. J Pathol (2004) 1.60
First international consensus on the methodology of lymphangiogenesis quantification in solid human tumours. Br J Cancer (2006) 1.53
Hepatocyte growth factor is a lymphangiogenic factor with an indirect mechanism of action. Blood (2006) 1.52
Cyclooxygenase-2 induces EP1- and HER-2/Neu-dependent vascular endothelial growth factor-C up-regulation: a novel mechanism of lymphangiogenesis in lung adenocarcinoma. Cancer Res (2004) 1.48
Human semaphorins A(V) and IV reside in the 3p21.3 small cell lung cancer deletion region and demonstrate distinct expression patterns. Proc Natl Acad Sci U S A (1996) 1.48
Vascular endothelial growth factor D is dispensable for development of the lymphatic system. Mol Cell Biol (2005) 1.47
Immunoelectron microscopic characterization of human dermal lymphatic microvascular endothelial cells. Differential expression of CD31, CD34, and type IV collagen with lymphatic endothelial cells vs blood capillary endothelial cells in normal human skin, lymphangioma, and hemangioma in situ. J Histochem Cytochem (1998) 1.47
HGF/NK4, a four-kringle antagonist of hepatocyte growth factor, is an angiogenesis inhibitor that suppresses tumor growth and metastasis in mice. Cancer Res (2000) 1.47
Chemokine-mediated migration of melanoma cells towards lymphatics--a mechanism contributing to metastasis. Oncogene (2006) 1.44
A close-up view of migrating Langerhans cells in the skin. J Invest Dermatol (2002) 1.43
Distinct 3p21.3 deletions in lung cancer and identification of a new human semaphorin. Oncogene (1996) 1.42
Lymphangiogenic growth factor responsiveness is modulated by postnatal lymphatic vessel maturation. Am J Pathol (2006) 1.39
COX-2-mediated stimulation of the lymphangiogenic factor VEGF-C in human breast cancer. Br J Cancer (2006) 1.39
Expression of vascular endothelial growth factor (VEGF)-C and VEGF-D, and their receptor VEGFR-3, during different stages of cervical carcinogenesis. J Pathol (2003) 1.39
Tumor-secreted vascular endothelial growth factor-C is necessary for prostate cancer lymphangiogenesis, but lymphangiogenesis is unnecessary for lymph node metastasis. Cancer Res (2005) 1.33
Recurrent endometrial cancer: patterns of recurrent disease and assessment of prognosis. Clin Radiol (2007) 1.33
Vascular endothelial growth factor-A mediates ultraviolet B-induced impairment of lymphatic vessel function. Am J Pathol (2006) 1.31
Vascular endothelial growth factor (VEGF)-C differentially affects tumor vascular function and leukocyte recruitment: role of VEGF-receptor 2 and host VEGF-A. Cancer Res (2001) 1.30
Metastatic cutaneous squamous cell carcinoma: an update. Dermatol Surg (2007) 1.29
Lymphangiogenic gene therapy with minimal blood vascular side effects. J Exp Med (2002) 1.29
Thrombospondin-1 selectively inhibits early-stage carcinogenesis and angiogenesis but not tumor lymphangiogenesis and lymphatic metastasis in transgenic mice. Oncogene (2002) 1.27
Coexpression of cyclooxygenases (COX-1, COX-2) and vascular endothelial growth factors (VEGF-A, VEGF-C) in esophageal adenocarcinoma. Cancer Res (2005) 1.25
Lymphangiogenesis correlates with lymph node metastasis, prognosis, and angiogenic phenotype in human non-small cell lung cancer. Clin Cancer Res (2005) 1.24
Lymphatic mapping and sentinel node analysis: current concepts and applications. CA Cancer J Clin (2006) 1.24
Inhibition of basic fibroblast growth factor expression, angiogenesis, and growth of human bladder carcinoma in mice by systemic interferon-alpha administration. Cancer Res (1998) 1.24
Lymphangiogenesis new mechanisms. Ann N Y Acad Sci (2002) 1.23
Differential in vivo and in vitro expression of vascular endothelial growth factor (VEGF)-C and VEGF-D in tumors and its relationship to lymphatic metastasis in immunocompetent rats. Cancer Res (2003) 1.22
Lymphatic function, lymphangiogenesis, and cancer metastasis. Microsc Res Tech (2001) 1.22
Isolation of the human semaphorin III/F gene (SEMA3F) at chromosome 3p21, a region deleted in lung cancer. Genomics (1996) 1.21
Lipocalin 2 promotes breast cancer progression. Proc Natl Acad Sci U S A (2009) 2.08
Epoxyeicosanoids stimulate multiorgan metastasis and tumor dormancy escape in mice. J Clin Invest (2011) 1.74
Tumor endothelial cells express epidermal growth factor receptor (EGFR) but not ErbB3 and are responsive to EGF and to EGFR kinase inhibitors. Cancer Res (2006) 1.67
Role of class 3 semaphorins and their receptors in tumor growth and angiogenesis. Clin Cancer Res (2009) 1.18
Epoxyeicosanoids promote organ and tissue regeneration. Proc Natl Acad Sci U S A (2013) 1.08
Soluble neuropilin targeted to the skin inhibits vascular permeability. Angiogenesis (2005) 1.08
Netrin-1 promotes glioblastoma cell invasiveness and angiogenesis by multiple pathways including activation of RhoA, cathepsin B, and cAMP-response element-binding protein. J Biol Chem (2012) 1.05
Targeting EGFR activity in blood vessels is sufficient to inhibit tumor growth and is accompanied by an increase in VEGFR-2 dependence in tumor endothelial cells. Microvasc Res (2008) 1.03
Vitamin D binding protein-macrophage activating factor directly inhibits proliferation, migration, and uPAR expression of prostate cancer cells. PLoS One (2010) 1.03
DIAPH3 governs the cellular transition to the amoeboid tumour phenotype. EMBO Mol Med (2012) 1.01
α(V)β(3) integrin-targeted PLGA-PEG nanoparticles for enhanced anti-tumor efficacy of a Pt(IV) prodrug. ACS Nano (2012) 1.00
Melanocyte-secreted fibromodulin promotes an angiogenic microenvironment. J Clin Invest (2013) 0.99
Cytoskeletal stiffness, friction, and fluidity of cancer cell lines with different metastatic potential. Clin Exp Metastasis (2012) 0.93
Regulation of epithelial plasticity by miR-424 and miR-200 in a new prostate cancer metastasis model. Sci Rep (2013) 0.91
Regulation of soluble neuropilin 1, an endogenous angiogenesis inhibitor, in liver development and regeneration. Pathology (2014) 0.79
Behavioral profiling of human transitional cell carcinoma ex vivo. Cancer Res (2006) 0.76
Increased endothelial progenitor cells and vasculogenic factors in higher-staged arteriovenous malformations. Plast Reconstr Surg (2011) 0.75
The intragraft microenvironment as a central determinant of chronic rejection or local immunoregulation/tolerance. Curr Opin Organ Transplant (2016) 0.75